NewAmsterdam Pharma (NASDAQ:NAMSW) Sees Large Decline in Short Interest

NewAmsterdam Pharma (NASDAQ:NAMSW) saw a significant drop in short interest in September. As of September 15th, there was short interest totaling 2,100 shares, a drop of 27.6% from the August 31st total of 2,900 shares. Based on an average daily volume of 4,000 shares, the days-to-cover ratio is currently 0.5 days. Based on an average daily volume of 4,000 shares, the days-to-cover ratio is currently 0.5 days.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in NewAmsterdam Pharma stock. Affinity Asset Advisors LLC lifted its holdings in NewAmsterdam Pharma (NASDAQ:NAMSW) by 1.3% during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 245,000 shares of the company’s stock after buying an additional 3,043 shares during the period. Affinity Asset Advisors LLC’s holdings in NewAmsterdam Pharma were worth $1,960,000 at the end of the most recent reporting period.

NewAmsterdam Pharma Price Performance

NASDAQ NAMSW opened at $20.75 on Tuesday. The business has a fifty day simple moving average of $14.13 and a 200 day simple moving average of $10.79. NewAmsterdam Pharma has a 12 month low of $5.45 and a 12 month high of $22.00.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.